share_log

Pharma Company Organicell Partners With Beauty Health Focusing On Aging & Inflammation Signs

Pharma Company Organicell Partners With Beauty Health Focusing On Aging & Inflammation Signs

制药公司Organicell与Beauty Health合作，专注于衰老和炎症迹象
Benzinga Real-time News ·  2022/09/16 11:16
  • Biopharmaceutical company Organicell Regenerative Medicine Inc (OTC:OCEL) plans to expand into the skincare and haircare industries in partnership with Beauty Health Co (NASDAQ:SKIN).
  • BeautyHealth's Hydrafacial, with Organicell, will create the first to-market exosome booster for their patented Hydrafacial device.
  • Hydrafacial's new exosome booster will be available early next year.
  • Organicell is a clinical-stage biopharmaceutical company focused on developing innovative biological therapeutics and regenerative medicine.
  • Organicell's science team will work with Hydrafacial to prove the efficacy of how this new booster application may reduce inflammation, increase collagen, and increase elastin.
  • "This partnership is the first of many we are working on in the aesthetic and hair space," said Organicell's CEO, Matt Sinnreich.
  • Last week, Organicell secured an additional $11 million in financing in preparation for clinical trial enrollment.
  • Organicell has been approved by the FDA to conduct Phase I/II clinical trials on their investigational new drug, Zofin.
  • Price Action: OCEL shares are trading higher by 4.13% at $0.05 on the last check Friday.
  • 生物制药公司Organicell再生医学公司(场外交易代码：OCEL)计划与以下公司合作进军护肤和护发行业美容保健公司(纳斯达克：皮肤)。
  • BeautyHealth的HydraFacial将与Organicell合作，为他们的专利HydraFacial设备创造第一个上市的外体助推器。
  • HydraFacal的新Exosome助推器将于明年初上市。
  • Organicell是一家临床阶段的生物制药公司，专注于开发创新的生物疗法和再生医学。
  • Organicell的科学团队将与HydraFacial合作，证明这种新的助推剂应用程序如何减少炎症、增加胶原蛋白和增加弹性蛋白的有效性。
  • Organicell首席执行官马特·辛瑞奇表示：“这是我们在美容和头发领域开展的众多合作中的第一个。”
  • 上周，Organicell获得了另外1100万美元的融资，为临床试验登记做准备。
  • Organicell已经获得FDA的批准，可以对他们的研究新药Zofin进行I/II期临床试验.
  • 价格行动：在周五的最后一次检查中，OCEL的股价上涨了4.13%，达到0.05美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发